Novartis Sees Sustaining Long-Term Growth With Potential Blockbusters

Novartis AG (NOVN.EB) said Thursday that it expects to sustain long-term growth with a pipeline of more than 25 potential blockbuster drugs.

“The near term brings yet another catalyst-rich period with pipeline progress across the portfolio that can sustain long-term growth,” said Chief Executive Vas Narasimhan.

The Swiss drug giant said it counts 60 projects in Phase 2 pipeline with more than 10 advancing into Phase 3 or pivotal trials each year in the 2020-21 period. Over 90% are projected to be “first-in-class or first-in-indication,” it said.

https://www.marketscreener.com/NOVARTIS-9364983/news/Novartis-Expects-to-Sustain-Long-Term-Growth-With-Pipeline-of-Potential-Blockbuster-Drugs-29683880/